Merck Will Study Cancidas/Antifungal Combinations In Phase IV Trials
Executive Summary
Merck will study Cancidas in combination with other antifungals for invasive aspergillosis treatment.
You may also be interested in...
Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic
Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines
Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic
Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines
Merck Cancidas Label Should Highlight Cyclosporine Data - FDA Committee
Labeling for Merck's antifungal Cancidas should include all available data on concomitant use with cyclosporine, although coadministration of the products is not recommended, FDA's Antiviral Drug Products Advisory Committee said Jan. 10.